Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies
Top Cited Papers
Open Access
- 1 May 2015
- journal article
- Published by Elsevier BV in Kidney International
- Vol. 87 (5), 1061-1073
- https://doi.org/10.1038/ki.2014.423
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic SyndromeThe New England Journal of Medicine, 2013
- Recessive mutations in DGKE cause atypical hemolytic-uremic syndromeNature Genetics, 2013
- The use of eculizumab in renal transplantationClinical Transplantation, 2013
- Eculizumab for Atypical Hemolytic Uremic Syndrome Recurrence in Renal TransplantationAmerican Journal of Transplantation, 2012
- Quality of Life in Patients Undergoing Hemodialysis or Peritoneal Dialysis TreatmentJournal of Clinical Medicine Research, 2011
- Relative Role of Genetic Complement Abnormalities in Sporadic and Familial aHUS and Their Impact on Clinical PhenotypeClinical Journal of the American Society of Nephrology, 2010
- Thrombomodulin Mutations in Atypical Hemolytic–Uremic SyndromeThe New England Journal of Medicine, 2009
- Podocyte Repopulation Contributes to Regression of Glomerular Injury Induced by Ace InhibitionThe American Journal of Pathology, 2009
- Estimation of minimally important differences in EQ-5D utility and VAS scores in cancerHealth and Quality of Life Outcomes, 2007
- EQ-SD: a measure of health status from the EuroQol GroupAnnals of Medicine, 2001